Outset Medical (NASDAQ:OM) Downgraded to “Sell” Rating by Wall Street Zen

Outset Medical (NASDAQ:OM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other equities analysts have also recently issued reports on OM. Stifel Nicolaus dropped their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $10.67.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $4.56 on Friday. Outset Medical has a one year low of $3.10 and a one year high of $21.98. The firm has a market capitalization of $82.76 million, a price-to-earnings ratio of -0.35 and a beta of 2.07. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $5.21 and a 200 day simple moving average of $11.92.

Hedge Funds Weigh In On Outset Medical

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in shares of Outset Medical in the second quarter valued at approximately $34,000. Ameritas Investment Partners Inc. acquired a new position in Outset Medical during the second quarter valued at approximately $35,000. BNP Paribas Financial Markets grew its stake in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Outset Medical during the 2nd quarter worth approximately $78,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Outset Medical during the 2nd quarter worth approximately $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.